
Conference Coverage
about 2 hours ago
Specialty Pharmacists Flag Symptoms, Sustain Adherence in ATTR-CMabout 5 hours ago
Community Oncology Delivers Strong Outcomes: Nicolas FerreyrosLatest Content

Medicare Leads 10 Countries on Access to Care but Lags on Affordability

Specialty Pharmacists Flag Symptoms, Sustain Adherence in ATTR-CM

Diagnostic Delays Linked to Greater Disease Activity, Worse Quality of Life in Sjögren Disease

5 Things to Know About Eye Injury Prevention Month

Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL

Shorts










Center on Health Equity & Access
All News

Teva's Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.

Population growth and aging, not rising age-standardized rates, drives the increase, with underlying causes varying widely by age and region.

The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.

Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.

Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.

The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."

The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.

A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.






























